62 results
PRE 14A
ALGS
Aligos Therapeutics Inc
16 Apr 24
Preliminary proxy
5:27pm
Corp., a publicly traded special purpose acquisition company from September 2020 to August 2021, and AveXis, Inc., a publicly traded gene therapy company … . Reducing the number of post-split stockholders, however, is not the purpose of this proposal.
Stockholders should be aware that, under the escheat
S-8
ALGS
Aligos Therapeutics Inc
12 Mar 24
Registration of securities for employees
4:51pm
in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $0.88 per share, which is the average
SC TO-I
EX-99
bh6t8lj3li6awwnm
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
8ixytepbs
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
opo2olbibpm6y wl
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
timqz 61wbe
30 Jan 24
Issuer tender offer statement
7:04am
424B3
hziqok x7a5kx94f
28 Nov 23
Prospectus supplement
4:01pm
8-K
EX-10.1
lgok8r1l6a6
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm
8-K
EX-4.1
ys2hku2m2uc ogd1
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm
8-K
EX-4.2
d3d4 s8jg
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm
DEFR14A
70dooxvqbk rfk
2 Jun 23
Revised proxy
4:05pm